SUSTAINABILITY OF RESPONSE BETWEEN UPADACITINIB AND ADALIMUMAB AMONG PATIENTS WITH RHEUMATOID ARTHRITIS AND PRIOR INADEQUATE RESPONSE TO METHOTREXATE

被引：0
|
作者：
Nash, Peter [1 ]
Kavanaugh, Arthur [2 ]
Buch, Maya [3 ]
Combe, Bernard [4 ]
Bessette, Louis [5 ]
Song, In-Ho [6 ]
Song, Yanna [6 ]
Suboticki, Jessica [6 ]
Fleischmann, Roy [7 ]
机构：
[1] Griffith Univ, Brisbane, Qld, Australia
[2] Univ Calif San Diego, Sch Med, Div Rheumatol Allergy & Immunol, San Diego, CA 92103 USA
[3] Univ Manchester, Sch Biol Sci, Ctr Musculoskeletal Res, Machester, England
[4] Univ Montpellier, Montpellier, France
[5] Laval Univ, Quebec City, PQ, Canada
[6] Abbvie Inc, N Chicago, IL USA
[7] Southwestern Med Ctr, Metroplex Clin Res Ctr, Dallas, TX USA
来源：
INTERNAL MEDICINE JOURNAL | 2021年 / 51卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P107
引用
收藏
页码：46 / 47
页数：2
相关论文
共 50 条
  • [31] Adalimumab In Combination With High and Low Dose-Methotrexate In Rheumatoid Arthritis Patients With Inadequate Response To Methotrexate: Pharmacokinetic Results From The Musica Study
    Ahmed, Ghada
    Goss, Sandra L.
    Klein, Cheri E.
    Mozaffarian, Neelufar
    Kaeley, Gurjit S.
    Awni, Walid
    ARTHRITIS AND RHEUMATISM, 2013, 65 : S623 - S624
  • [32] EFFICACY AND SAFETY OF ADALIMUMAB WITH LOW AND HIGH DOSE-METHOTREXATE IN PATIENTS WITH RHEUMATOID ARTHRITIS WITH INADEQUATE RESPONSE TO METHOTREXATE: THE RANDOMISED CONTROLLED MIRACLE STUDY
    Tamai, H.
    Ikeda, K.
    Miyamoto, T.
    Taguchi, H.
    Kuo, C. F.
    Shin, K.
    Hirata, S.
    Okano, Y.
    Sato, S.
    Yasuoka, H.
    Choi, I. A.
    Park, S. H.
    Weng, M. Y.
    Kuwana, M.
    Lee, Y. J.
    Ishii, T.
    Kim, J.
    Kameda, H.
    Kojima, T.
    Baek, H. J.
    Hsu, P. N.
    Huang, C. M.
    Cheng, T. T.
    Sung, W. Y.
    Taninaga, T.
    Mori, M.
    Miyagishi, H.
    Sato, Y.
    Takeuchi, T.
    Kaneko, Y.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 42 - 43
  • [33] Infiltrations of plasma cells in synovium predict inadequate response to Adalimumab in Rheumatoid Arthritis patients
    Li, Jian Bin
    Liu, Peng Cheng
    Chen, Liming
    Wu, Rui
    ARTHRITIS RESEARCH & THERAPY, 2024, 26 (01)
  • [34] Upadacitinib in Patients with Rheumatoid Arthritis and Inadequate Response or Intolerance to Biological DMARDs: Results at 60 Weeks
    Genovese, Mark
    Combe, Bernard
    Hall, Stephen
    Rubbert-Roth, Andrea
    Zhong, Sheng
    Meerwein, Sebastian
    Pangan, Aileen
    Fleischmann, Roy
    ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [35] Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response
    Fleischmann, Roy M.
    Genovese, Mark C.
    Enejosa, Jeffrey V.
    Mysler, Eduardo
    Bessette, Louis
    Peterfy, Charles
    Durez, Patrick
    Ostor, Andrew
    Li, Yihan
    Song, In-Ho
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 (11) : 1454 - 1462
  • [36] UPADACITINIB IMPROVES PATIENT-REPORTED OUTCOMES IN PATIENTS WITH RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE TO METHOTREXATE: RESULTS FROM SELECT-COMPARE
    Strand, Vibeke
    Bergman, Martin
    Tundia, Namita
    Ostor, Andrew
    Durez, Patrick
    Song, In-Ho
    Enejosa, Jose Jeffrey
    Schlacher, Casey
    Song, Yan
    Fleischmann, Roy
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 738 - 739
  • [37] Upadacitinib As Monotherapy: A Phase 3 Randomized Controlled Double-Blind Study in Patients with Active Rheumatoid Arthritis and Inadequate Response to Methotrexate
    Smolen, Josef S.
    Cohen, Stanley
    Emery, Paul
    Rigby, William F. C.
    Tanaka, Yoshiya
    Zhang, Ying
    Friedman, Alan
    Othman, Ahmed A.
    Camp, Heidi S.
    Pangan, Aileen L.
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [38] UPADACITINIB AS MONOTHERAPY: A PHASE 3 RANDOMIZED CONTROLLED DOUBLE-BLIND STUDY IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE TO METHOTREXATE
    Smolen, J. S.
    Cohen, S.
    Emery, P.
    Rigby, W.
    Tanaka, Y.
    Zhang, Y.
    Friedman, A.
    Othman, A. A.
    Camp, H. S.
    Pangan, A. L.
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2019, 25 : S52 - S52
  • [39] UPADACITINIB AS MONOTHERAPY: A PHASE 3 RANDOMISED CONTROLLED DOUBLE-BLIND STUDY IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE TO METHOTREXATE
    Smolen, J. S.
    Cohen, S.
    Emery, P.
    Rigby, W.
    Tanaka, Y.
    Zhang, Y.
    Friedman, A.
    Othman, A. A.
    Camp, H. S.
    Pangan, A. L.
    RHEUMATOLOGY, 2019, 58
  • [40] UPADACITINIB AS MONOTHERAPY: A PHASE 3 RANDOMISED CONTROLLED DOUBLE-BLIND STUDY IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE TO METHOTREXATE
    Smolen, J.
    Cohen, S.
    Emery, P.
    Rigby, W.
    Tanaka, Y.
    Zhang, Y.
    Friedman, A.
    Othman, A.
    Camp, H.
    Pangan, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 67 - 68
12345